Floatz logo

FUROSEMIDE

Cirrhosis

Stacy JohnsonSmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
73/ 100

Competitive context

142 Active assets in the Cirrhosis cohort.

Asset / SponsorPhaseRating
PARITAPREVIR
AbbVie
Phase 3A
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE)
General Hospital of Shenyang Military Region
Phase 4BBB
Tolvaptan
Institute of Liver and Biliary Sciences, India
Phase 4BBB
Ribavirin
Peking University People's Hospital
Phase 4BBB
NORMAL HUMAN SERUM ALBUMIN
King George's Medical University
Phase 4BBB

View all 50 →

Same molecule, other indications

FUROSEMIDE is also rated in:

AscitesDormant
BB
Indicative ·
70 / 100
View asset →
Fluid OverloadDormant
BB
Indicative ·
65 / 100
View asset →
Volume OverloadDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →